These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1057 related items for PubMed ID: 20060824

  • 1. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
    Ganser C, Papazoglou A, Just L, Nikkhah G.
    Exp Cell Res; 2010 Mar 10; 316(5):737-46. PubMed ID: 20060824
    [Abstract] [Full Text] [Related]

  • 2. Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease.
    Kanaan NM, Collier TJ, Marchionini DM, McGuire SO, Fleming MF, Sortwell CE.
    Brain Res; 2006 Jan 12; 1068(1):221-9. PubMed ID: 16368081
    [Abstract] [Full Text] [Related]

  • 3. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
    Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Wen Ji Y, Hayase H, Hamada H, Borlongan CV, Date I.
    Brain Res; 2005 Aug 16; 1053(1-2):10-8. PubMed ID: 16045899
    [Abstract] [Full Text] [Related]

  • 4. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.
    Ding YM, Jaumotte JD, Signore AP, Zigmond MJ.
    J Neurochem; 2004 May 16; 89(3):776-87. PubMed ID: 15086533
    [Abstract] [Full Text] [Related]

  • 5. Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures.
    Zhang L, Fletcher-Turner A, Marchionni MA, Apparsundaram S, Lundgren KH, Yurek DM, Seroogy KB.
    J Neurochem; 2004 Dec 16; 91(6):1358-68. PubMed ID: 15584912
    [Abstract] [Full Text] [Related]

  • 6. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
    Yasuhara T, Shingo T, Kobayashi K, Takeuchi A, Yano A, Muraoka K, Matsui T, Miyoshi Y, Hamada H, Date I.
    Eur J Neurosci; 2004 Mar 16; 19(6):1494-504. PubMed ID: 15066146
    [Abstract] [Full Text] [Related]

  • 7. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue.
    Andres RH, Huber AW, Schlattner U, Pérez-Bouza A, Krebs SH, Seiler RW, Wallimann T, Widmer HR.
    Neuroscience; 2005 Mar 16; 133(3):701-13. PubMed ID: 15890457
    [Abstract] [Full Text] [Related]

  • 8. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis.
    Kadota T, Shingo T, Yasuhara T, Tajiri N, Kondo A, Morimoto T, Yuan WJ, Wang F, Baba T, Tokunaga K, Miyoshi Y, Date I.
    Brain Res; 2009 Feb 13; 1254():120-7. PubMed ID: 19101524
    [Abstract] [Full Text] [Related]

  • 9. G-CSF protects dopaminergic neurons from 6-OHDA-induced toxicity via the ERK pathway.
    Huang HY, Lin SZ, Kuo JS, Chen WF, Wang MJ.
    Neurobiol Aging; 2007 Aug 13; 28(8):1258-69. PubMed ID: 16839644
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
    Andereggen L, Meyer M, Guzman R, Ducray AD, Widmer HR.
    Brain Res; 2009 Jun 18; 1276():39-49. PubMed ID: 19389387
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3.
    Ebert AD, Hann HJ, Bohn MC.
    J Neurosci Res; 2008 Feb 01; 86(2):317-25. PubMed ID: 17787016
    [Abstract] [Full Text] [Related]

  • 15. Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease.
    Shim JS, Kim HG, Ju MS, Choi JG, Jeong SY, Oh MS.
    J Ethnopharmacol; 2009 Nov 12; 126(2):361-5. PubMed ID: 19703534
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons.
    Rodriguez-Pallares J, Parga JA, Muñoz A, Rey P, Guerra MJ, Labandeira-Garcia JL.
    J Neurochem; 2007 Oct 12; 103(1):145-56. PubMed ID: 17573824
    [Abstract] [Full Text] [Related]

  • 18. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.
    Yasuhara T, Shingo T, Muraoka K, wen Ji Y, Kameda M, Takeuchi A, Yano A, Nishio S, Matsui T, Miyoshi Y, Hamada H, Date I.
    Brain Res; 2005 Mar 15; 1038(1):1-10. PubMed ID: 15748867
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.